ICOS agonism by JTX-2011 (vopratelimab) requires initial T cell priming and Fc cross-linking for optimal T cell activation and anti-tumor immunity in preclinical models

Immunotherapy checkpoint inhibitors, such as antibodies targeting PD-1 and CTLA-4, have demonstrated the potential of harnessing the immune system to treat cancer. However, despite encouraging results particularly with respect to survival, only a minority of patients benefit from these therapies. In...

Descripción completa

Detalles Bibliográficos
Autores principales: Hanson, Amanda, Elpek, Kutlu, Duong, Ellen, Shallberg, Lindsey, Fan, Martin, Johnson, Calvin, Wallace, Matthew, Mabry, George R., Sazinsky, Stephen, Pepper, Lauren, Shu, Chengyi J., Sathyanarayanan, Sriram, Zuerndorfer, Sarah, Simpson, Tyler, Gostissa, Monica, Briskin, Michael, Law, Deborah, Michaelson, Jennifer, Harvey, Christopher J.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Public Library of Science 2020
Materias:
Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7514066/
https://www.ncbi.nlm.nih.gov/pubmed/32970735
http://dx.doi.org/10.1371/journal.pone.0239595

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7514066/
https://www.ncbi.nlm.nih.gov/pubmed/32970735
http://dx.doi.org/10.1371/journal.pone.0239595

Ejemplares similares